Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting

Letizia MARINARO; Andrea CALCAGNO; Diego Ripamonti; Giovanni Cenderello; VERONICA PIRRIATORE; Laura TRENTINI; Bernardino Salassa; Caterina Bramato; GIANCARLO OROFINO; ANTONIO D'AVOLIO; Marco Rizzi; Giovanni DI PERRI; Stefano Rusconi; Stefano BONORA

doi:10.1016/j.jcv.2016.11.015

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting

Letizia MARINARO
, Andrea CALCAGNO
, Diego Ripamonti
, Giovanni Cenderello
, VERONICA PIRRIATORE
, Laura TRENTINI
, Bernardino Salassa
, Caterina Bramato
, GIANCARLO OROFINO
, ANTONIO D'AVOLIO
, Marco Rizzi
, Giovanni DI PERRI
, Stefano Rusconi
, Stefano BONORA

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Unboosted atazanavir with raltegravir has been investigated at 300mg twice daily showing frequent hyperbilirubinemia and selection of resistance-associated mutations.

Lingua originale	Inglese
pagine (da-a)	30-36
Numero di pagine	7
Rivista	Journal of Clinical Virology
Volume	87
DOI	https://doi.org/10.1016/j.jcv.2016.11.015
Stato di pubblicazione	Pubblicato - 2017

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Atazanavir
HIV
NRTI-sparing antiretroviral therapy
Raltegravir
Treatment-experienced patients

Accesso al documento

10.1016/j.jcv.2016.11.015

https://hdl.handle.net/11579/217037

Altri file e collegamenti

handle

Cita questo

MARINARO, L., CALCAGNO, A., Ripamonti, D., Cenderello, G., PIRRIATORE, VERONICA., TRENTINI, L., Salassa, B., Bramato, C., OROFINO, GIANCARLO., D'AVOLIO, ANTONIO., Rizzi, M., DI PERRI, G., Rusconi, S., & BONORA, S. (2017). Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. Journal of Clinical Virology, 87, 30-36. https://doi.org/10.1016/j.jcv.2016.11.015

@article{c1e2c58a6c174dfc8a7c01b8f9a82eb2,

title = "Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting",

abstract = "Unboosted atazanavir with raltegravir has been investigated at 300mg twice daily showing frequent hyperbilirubinemia and selection of resistance-associated mutations.",

keywords = "Atazanavir, HIV, NRTI-sparing antiretroviral therapy, Raltegravir, Treatment-experienced patients, Atazanavir, HIV, NRTI-sparing antiretroviral therapy, Raltegravir, Treatment-experienced patients",

author = "Letizia MARINARO and Andrea CALCAGNO and Diego Ripamonti and Giovanni Cenderello and VERONICA PIRRIATORE and Laura TRENTINI and Bernardino Salassa and Caterina Bramato and GIANCARLO OROFINO and ANTONIO D'AVOLIO and Marco Rizzi and \{DI PERRI\}, Giovanni and Stefano Rusconi and Stefano BONORA",

year = "2017",

doi = "10.1016/j.jcv.2016.11.015",

language = "English",

volume = "87",

pages = "30--36",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier B.V.",

}

MARINARO, L, CALCAGNO, A, Ripamonti, D, Cenderello, G, PIRRIATORE, VERONICA, TRENTINI, L, Salassa, B, Bramato, C, OROFINO, GIANCARLO, D'AVOLIO, ANTONIO, Rizzi, M, DI PERRI, G, Rusconi, S & BONORA, S 2017, 'Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting', Journal of Clinical Virology, vol. 87, pagg. 30-36. https://doi.org/10.1016/j.jcv.2016.11.015

TY - JOUR

T1 - Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting

AU - MARINARO, Letizia

AU - CALCAGNO, Andrea

AU - Ripamonti, Diego

AU - Cenderello, Giovanni

AU - PIRRIATORE, VERONICA

AU - TRENTINI, Laura

AU - Salassa, Bernardino

AU - Bramato, Caterina

AU - OROFINO, GIANCARLO

AU - D'AVOLIO, ANTONIO

AU - Rizzi, Marco

AU - DI PERRI, Giovanni

AU - Rusconi, Stefano

AU - BONORA, Stefano

PY - 2017

Y1 - 2017

N2 - Unboosted atazanavir with raltegravir has been investigated at 300mg twice daily showing frequent hyperbilirubinemia and selection of resistance-associated mutations.

AB - Unboosted atazanavir with raltegravir has been investigated at 300mg twice daily showing frequent hyperbilirubinemia and selection of resistance-associated mutations.

KW - Atazanavir

KW - HIV

KW - NRTI-sparing antiretroviral therapy

KW - Raltegravir

KW - Treatment-experienced patients

KW - Atazanavir

KW - HIV

KW - NRTI-sparing antiretroviral therapy

KW - Raltegravir

KW - Treatment-experienced patients

UR - https://iris.uniupo.it/handle/11579/217037

U2 - 10.1016/j.jcv.2016.11.015

DO - 10.1016/j.jcv.2016.11.015

M3 - Article

SN - 1386-6532

VL - 87

SP - 30

EP - 36

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

ER -

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo